WS Investor
29 Sep 2026, 19:54
Johnson & Johnson Highlights Two-Year IMAAVY Data Showing Sustained Disease Control in gMG
Johnson & Johnson reported new two-year data for IMAAVY in generalized myasthenia gravis, showing sustained improvements in daily function and muscle strength among adolescents treated in the Phase 2/3 Vibrance-MG study.
At Week 108, patients with available data maintained a mean 2.88-point improvement in the MG-ADL score and an 8.25-point improvement in the QMG score from baseline. Corticosteroid use also declined, with three of six adolescents taking steroids at study entry reducing their dose and one discontinuing treatment after two years. No new safety signals were identified.
Johnson & Johnson also presented retrospective real-world data from healthcare professionals treating adults with anti-AChR or anti-MuSK antibody-positive gMG. Fluctuating symptom control was cited as the most common reason for stopping a previous advanced therapy.
Among 97 patients who switched to IMAAVY, 73.2% were reported as “much improved” or “very much improved.” Among patients receiving prednisone, 76.4% reduced their dose and 5.5% discontinued it.
IMAAVY is an FcRn blocker approved for adults and patients aged 12 and older with antibody-positive generalized myasthenia gravis. The new findings add longer-term evidence supporting sustained disease control and reduced corticosteroid dependence.
Johnson & Johnson reported new two-year data for IMAAVY in generalized myasthenia gravis, showing sustained improvements in daily function and muscle strength among adolescents treated in the Phase 2/3 Vibrance-MG study.
At Week 108, patients with available data maintained a mean 2.88-point improvement in the MG-ADL score and an 8.25-point improvement in the QMG score from baseline. Corticosteroid use also declined, with three of six adolescents taking steroids at study entry reducing their dose and one discontinuing treatment after two years. No new safety signals were identified.
Johnson & Johnson also presented retrospective real-world data from healthcare professionals treating adults with anti-AChR or anti-MuSK antibody-positive gMG. Fluctuating symptom control was cited as the most common reason for stopping a previous advanced therapy.
Among 97 patients who switched to IMAAVY, 73.2% were reported as “much improved” or “very much improved.” Among patients receiving prednisone, 76.4% reduced their dose and 5.5% discontinued it.
IMAAVY is an FcRn blocker approved for adults and patients aged 12 and older with antibody-positive generalized myasthenia gravis. The new findings add longer-term evidence supporting sustained disease control and reduced corticosteroid dependence.
